CSI Market
Sign In | Register

Gene Biotherapeutics Inc (CRXM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CRXM Annual Cash Flow →
The table below presents a historical view of Gene Biotherapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2020)
12 Months 		(Sep 30 2020) (Jun 30 2020) (Mar 31 2020) (Dec 31 2019)
Operating Activities
Income-0.65
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventory Write-down0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges-0.60
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain On Sale Of Warrants-
Amortization Of Technology And Product License Fee-
In Process Purchased Technology-
Increase Decrease In Deferred Rent Receivables-
Subscription Receivable For Common Shares-
Common Stock Issued For Repayment Of Loans-
Amortization And Write Off Of Technology And Product Licenses-
Write Off Of Technology Licenses-
Deferred Rent Amortization0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.15
Increase (Decrease) in Accrued Liabilities0.33
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.01
Other Working Capital-0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.07
Discontinued operations0.00
Net Cash flow from Operating Activities-1.13
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Fee Paid To List Shares Issued For Technology And Product License-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.19
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.20
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.17
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock1.70
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.52
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.14
Total Cash Flow0.39
4 historic quarters locked

Sign in to unlock the full Gene Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Gene Biotherapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

  • Form:
  • Filed with the SEC: April 13, 2022

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-22-009863

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Get the full CSIMarket dataset: Subscribe API License